AgeChem Venture Fund

Overview

AgeChem Venture Fund is a venture capital firm specializing in early-stage investments in companies developing therapeutics targeting age-related diseases. The firm focuses on a broad spectrum of conditions associated with aging, including metabolic disorders, cardiovascular diseases, cancers, central nervous system diseases, and inflammatory diseases. By investing in these areas, AgeChem aims to support the development of innovative treatments that address the challenges posed by an aging global population. Established in 2006, AgeChem Venture Fund is based in Montreal, Quebec, Canada. The firm manages approximately $65 million in assets and seeks to invest in companies at various stages, from seed to Series B. Its geographical focus includes Canada, the United States, and Europe, reflecting a commitment to supporting innovative healthcare solutions across these regions. AgeChem's investment strategy involves active involvement within its portfolio companies, providing not only capital but also strategic guidance to foster growth and success. This hands-on approach is designed to accelerate the development of novel therapeutics and bring them to market more efficiently, ultimately improving patient outcomes and quality of life for those affected by age-related diseases.

Investment Focus

• Companies developing therapeutics for age-related diseases
• Early-stage companies
• Innovative healthcare solutions

Portfolio Companies